Singapore markets open in 6 hours 2 minutes
Straits Times Index
3,116.31 -49.19 (-1.55%) S&P 500
3,709.82 +62.53 (+1.71%) Dow
29,619.33 +484.34 (+1.66%) Nasdaq
11,016.33 +186.82 (+1.73%) BTC-USD
19,534.33 +400.88 (+2.10%) CMC Crypto 200
445.34 +16.56 (+3.86%)
Iovance Biotherapeutics, Inc. (IOVA)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
As of 02:57PM EDT. Market open.
| Previous close | 9.89 |
| Open | 10.03 |
| Bid | 10.22 x 800 |
| Ask | 10.23 x 800 |
| Day's range | 9.99 - 10.28 |
| 52-week range | 6.18 - 27.96 |
| Volume | |
| Avg. volume | 2,521,774 |
| Market cap | 1.613B |
| Beta (5Y monthly) | 0.50 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.30 |
| Earnings date | 02 Nov 2022 - 07 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 26.38 |
- Zacks
Iovance (IOVA) Starts Rolling BLA With FDA for Melanoma Therapy
Iovance (IOVA) starts a rolling BLA submission with the FDA seeking approval for its lead pipeline candidate in advanced melanoma patients. The filing is expected to be completed by fourth-quarter 2022.
- Zacks
Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track
Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
- Zacks
Iovance (IOVA) Pipeline Aids Growth Amid Lack of Marketed Drugs
Iovance (IOVA) is progressing well with the clinical development of its pipeline candidates. It expects to file a BLA with the FDA, seeking approval for its lead candidate to treat metastatic melanoma, this August.
© 2022 Yahoo. All rights reserved.
